Literature DB >> 16216103

Contribution of clonal dissemination and selection of mutants during therapy to Pseudomonas aeruginosa antimicrobial resistance in an intensive care unit setting.

C Juan1, O Gutiérrez, A Oliver, J I Ayestarán, N Borrell, J L Pérez.   

Abstract

Rates of antibiotic resistance in Pseudomonas aeruginosa isolates from intensive care unit (ICU) patients are expected to be dependent on the selection of resistance mutations during therapy, the availability of exogenous resistance determinants and their dissemination potential, and the efficiency of transmission of the resistant strains. The relative contributions of these three factors were studied in an ICU with no apparent outbreak in 216 sequential P. aeruginosa isolates recovered from 102 patients between September 2002 and November 2003. Analysis of pulsed-field gel electrophoresis patterns revealed the presence of 82 different clones. Thus, the dissemination of particular resistant clones had a minimal effect on the relatively high overall resistance frequencies found for imipenem (32%), cefepime (25%), ceftazidime (24%), meropenem (22%), ciprofloxacin (18%) and tobramycin (2%). Rates of primary resistance were relatively low, and resistance development during treatment (secondary resistance) was the main factor contributing to the overall high resistance rates. In ICU settings with a low prevalence of epidemic resistant strains, the main strategy for resistance control should focus on the design of targeted regimens to avoid the development of resistance.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16216103     DOI: 10.1111/j.1469-0691.2005.01251.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  24 in total

1.  Stepwise upregulation of the Pseudomonas aeruginosa chromosomal cephalosporinase conferring high-level beta-lactam resistance involves three AmpD homologues.

Authors:  Carlos Juan; Bartolomé Moyá; José L Pérez; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2006-05       Impact factor: 5.191

2.  Molecular mechanisms of beta-lactam resistance mediated by AmpC hyperproduction in Pseudomonas aeruginosa clinical strains.

Authors:  Carlos Juan; María D Maciá; Olivia Gutiérrez; Carmen Vidal; José L Pérez; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2005-11       Impact factor: 5.191

3.  Optimization of a Meropenem-Tobramycin Combination Dosage Regimen against Hypermutable and Nonhypermutable Pseudomonas aeruginosa via Mechanism-Based Modeling and the Hollow-Fiber Infection Model.

Authors:  Cornelia B Landersdorfer; Vanessa E Rees; Rajbharan Yadav; Kate E Rogers; Tae Hwan Kim; Phillip J Bergen; Soon-Ee Cheah; John D Boyce; Anton Y Peleg; Antonio Oliver; Beom Soo Shin; Roger L Nation; Jürgen B Bulitta
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191

4.  In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa.

Authors:  Shinobu Takeda; Toru Nakai; Yoshimi Wakai; Fumiaki Ikeda; Kazuo Hatano
Journal:  Antimicrob Agents Chemother       Date:  2006-12-04       Impact factor: 5.191

5.  Long-term use of selective decontamination of the digestive tract does not increase antibiotic resistance: a 5-year prospective cohort study.

Authors:  María E Ochoa-Ardila; Ana García-Cañas; Karen Gómez-Mediavilla; Ana González-Torralba; Inmaculada Alía; Paloma García-Hierro; Nia Taylor; Hendrick K F van Saene; Miguel A de la Cal
Journal:  Intensive Care Med       Date:  2011-07-19       Impact factor: 17.440

6.  Affinity of the new cephalosporin CXA-101 to penicillin-binding proteins of Pseudomonas aeruginosa.

Authors:  Bartolomé Moyá; Laura Zamorano; Carlos Juan; Yigong Ge; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2010-06-14       Impact factor: 5.191

7.  AmpG inactivation restores susceptibility of pan-beta-lactam-resistant Pseudomonas aeruginosa clinical strains.

Authors:  Laura Zamorano; Thomas M Reeve; Carlos Juan; Bartolomé Moyá; Gabriel Cabot; David J Vocadlo; Brian L Mark; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2011-02-28       Impact factor: 5.191

8.  Influence of high mutation rates on the mechanisms and dynamics of in vitro and in vivo resistance development to single or combined antipseudomonal agents.

Authors:  V Plasencia; N Borrell; M D Maciá; B Moya; J L Pérez; A Oliver
Journal:  Antimicrob Agents Chemother       Date:  2007-04-30       Impact factor: 5.191

9.  Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients.

Authors:  Bartolome Moya; Laura Zamorano; Carlos Juan; José L Pérez; Yigong Ge; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2010-01-19       Impact factor: 5.191

Review 10.  Cefepime: a reappraisal in an era of increasing antimicrobial resistance.

Authors:  Andrea Endimiani; Federico Perez; Robert A Bonomo
Journal:  Expert Rev Anti Infect Ther       Date:  2008-12       Impact factor: 5.091

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.